Edition:
United States

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

41.98USD
24 Mar 2017
Change (% chg)

$0.48 (+1.16%)
Prev Close
$41.50
Open
$41.65
Day's High
$42.26
Day's Low
$41.39
Volume
216,250
Avg. Vol
350,439
52-wk High
$55.15
52-wk Low
$33.57

Latest Key Developments (Source: Significant Developments)

Neurocrine Biosciences reports positive results from study of Ingrezza
Tuesday, 21 Mar 2017 08:59am EDT 

Neurocrine Biosciences Inc : Positive results from Kinect 3 phase iii study of Ingrezza (valbenazine) for treatment of tardive dyskinesia (td) . Has submitted NDA to FDA for ingrezza and has been granted priority review with a pdufa action date of April 11, 2017 .Says Ingrezza was found to be generally well tolerated with adverse events consistent with those of prior studies.  Full Article

Neurocrine Biosciences reports Q4 loss per share $0.51
Tuesday, 14 Feb 2017 04:24pm EST 

Neurocrine Biosciences Inc : Neurocrine Biosciences reports year-end 2016 results and provides investor update for 2017 . Q4 loss per share $0.51 . Q4 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S . Neurocrine Biosciences Inc- Revenues from milestones under abbvie agreement for 2017 are expected to be $30 million .Neurocrine Biosciences-2017 ongoing operating expenses should approximate $230 million to $240 million, exclusive of $30 million up-front fee for in-licensing opicapone.  Full Article

Neurocrine Biosciences CFO Timothy Coughlin to step down
Wednesday, 21 Dec 2016 04:01pm EST 

Neurocrine Biosciences Inc : Neurocrine Biosciences -Timothy P. Coughlin will be stepping down from his position as chief financial officer in mid-February for personal reasons . Neurocrine Biosciences -board has initiated replacement search and Coughlin has agreed to continue with co through 2017 .Neurocrine Biosciences announces chief financial officer Timothy P. Coughlin to step down.  Full Article

Neurocrine says INGREZZA NDA for treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA
Tuesday, 11 Oct 2016 06:55am EDT 

Neurocrine Biosciences Inc : Neurocrine announces INGREZZA™ (valbenazine) new drug application for the treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA .Neurocrine Biosciences Inc- INGREZZA application has been given a prescription drug user fee act (PDUFA) target action date of April 11, 2017.  Full Article

Neurocrine announces FDA conditional acceptance of Ingrezza
Wednesday, 31 Aug 2016 04:02pm EDT 

Neurocrine Biosciences Inc : Neurocrine announces FDA conditional acceptance of proprietary name Ingrezza™ for VMAT2 inhibitor valbenazine .Expects to receive notification of acceptance of NDA filing, as well as timeframe for NDA review from FDA in October 2016.  Full Article

Neurocrine submits NDA for Valbenazine
Monday, 29 Aug 2016 04:02pm EDT 

Neurocrine Biosciences Inc : Submits new drug application for Valbenazine for treatment of tardive dyskinesia .Expects to receive notification of acceptance of NDA, as well as timeframe for NDA review from FDA in october 2016..  Full Article

Neurocrine Biosciences Q2 loss per share $0.46
Wednesday, 3 Aug 2016 04:02pm EDT 

Neurocrine Biosciences Inc : Neurocrine biosciences reports second quarter 2016 results . Q2 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.46.  Full Article

Neurocrine Biosciences Inc announces positive results from phase III kinect 3 study of nbi-98854 in tardive dyskinesia
Thursday, 8 Oct 2015 06:30am EDT 

Neurocrine Biosciences Inc:Announces positive results from phase III kinect 3 study of nbi-98854 in tardive dyskinesia.Says study meets primary endpoint, submission of new drug application planned for 2016.Nbi-98854 showed statistically significant reduction in tardive dyskinesia during six weeks of placebo-controlled treatment.Says during the six-week placebo-controlled treatment period nbi-98854 was generally well tolerated.Clinical hematology, chemistry and ecg monitoring indicated no emergent safety signals.A separate 1-year open-label safety study of nbi-98854 been initiated to support the 2016 filing of nda in tardive dyskinesia.  Full Article

More From Around the Web

BRIEF-Neurocrine Biosciences reports positive results from study of Ingrezza

* Positive results from Kinect 3 phase iii study of Ingrezza (valbenazine) for treatment of tardive dyskinesia (td)